LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the preven
CAS Number:
[1629760-28-6]
Target:
hLIV22
* VAT and and shipping costs not included. Errors and price changes excepted